TSHA实时信号 | 通过Getagraph.com最大化利润

出售 112897 min ago

@ $1.475

发出时间: 15 Feb 2024 @ 04:29

回报率: 74.92%

上一信号: Feb 15 - 02:58

上一信号: 购买

回报率: 2.43 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Stats
今日成交量	1.49M
平均成交量	2.87M
市值	482.51M
EPS	$0 ( 2024-03-19 )
下一个收益日期	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.69
ATR14	$0.00800 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-02	Alam Kamran	Sell	1 288	Common Stock
2024-01-02	Alam Kamran	Buy	590 413	Common Stock
2024-01-02	Alam Kamran	Buy	590 413	Employee Stock Option (right to buy)
2024-01-02	Nagendran Sukumar	Buy	863 617	Common Stock
2024-01-02	Nagendran Sukumar	Buy	863 617	Employee Stock Option (right to buy)

INSIDER POWER
95.37
Last 97 transactions
Buy: 29 865 015 \| Sell: 943 112

音量相关性

長: 0.28 (neutral)

短: 0.02 (neutral)

Signal:(53.427) Neutral

Taysha Gene Therapies, 相关性

10 最正相关
BCYC	0.922
EAR	0.92
TRMK	0.91
ALNY	0.895
DTSS	0.887
XPDI	0.882
GOEV	0.876
GMII	0.872
GOOD	0.871
ALLK	0.87

10 最负相关
VTYX	-0.889
CNCE	-0.889
STTK	-0.888
FLXN	-0.888
DRNA	-0.886
THRY	-0.881
OCSL	-0.881
NPCE	-0.878
PLRX	-0.877
XM	-0.877

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Taysha Gene Therapies, 相关性 - 货币/商品

-0.04
( neutral )

0.05
( neutral )

0.00
( neutral )

-0.44
( neutral )

Taysha Gene Therapies, 财务报表

Annual	2023
营收:	$15.45M
毛利润:	$14.08M (91.13 %)
EPS:	$-0.960

FY	2023
营收:	$15.45M
毛利润:	$14.08M (91.13 %)
EPS:	$-0.960

FY	2022
营收:	$2.50M
毛利润:	$15 000.00 (0.60 %)
EPS:	$-3.86

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.64

Financial Reports:

No articles found.

Taysha Gene Therapies,

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.